# A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

> **NCT05824663** · PHASE1 · COMPLETED · sponsor: **Harbour BioMed US, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HBM1020

## Key facts

- **NCT ID:** NCT05824663
- **Lead sponsor:** Harbour BioMed US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-23
- **Primary completion:** 2024-10-09
- **Final completion:** 2024-10-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05824663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05824663, "A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05824663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*